| |
Prevalence, %
|
95% confidence intervals
|
No. studies
|
No. participants
|
Heterogeneity
|
Egger test
|
P value, difference
|
|---|
|
I2, %
|
P value
|
|---|
|
Global
|
36.1
|
33.7–38.5
|
329
|
462 104
|
99.5
|
< 0.0001
|
0.0002
|
…
|
|
All participants on ART
|
34.5
|
31.8–37.2
|
268
|
420 575
|
99.6
|
< 0.0001
|
0.0001
|
…
|
|
Country level of income
|
|
Low
|
10.1
|
6.8–14.1
|
30
|
11 329
|
95.9
|
< 0.0001
|
0.095
|
< 0.0001
|
|
Lower-middle
|
16.0
|
8.6–25.3
|
21
|
9858
|
98.7
|
< 0.0001
|
0.496
| |
|
Upper-middle
|
27.6
|
23.8–31.6
|
39
|
8252
|
90.4
|
< 0.0001
|
0.668
| |
|
High
|
45.2
|
42.7–47.7
|
216
|
339 022
|
99.5
|
< 0.0001
|
0.527
| |
|
UNAIDS region
|
|
West and Central Africa
|
4.4
|
2.9–6.3
|
12
|
4868
|
87.0
|
< 0.0001
|
0.263
|
< 0.0001
|
|
Eastern and Southern Africa
|
10.7
|
7.8–14.0
|
34
|
12 676
|
94.8
|
< 0.0001
|
0.080
| |
|
Latin America and the Caribbean
|
28.8
|
25.0–32.8
|
24
|
16 385
|
95.9
|
< 0.0001
|
0.162
| |
|
Asia and Pacific
|
32.6
|
26.6–38.9
|
27
|
16 352
|
97.3
|
< 0.0001
|
0.031
| |
|
Middle East and North Africa
|
32.9
|
16.1–52.4
|
3
|
320
|
93.0
|
< 0.0001
|
0.711
| |
|
Eastern Europe and Central Asia
|
43.1
|
15.8–72.9
|
2
|
264
|
95.9
|
< 0.0001
|
NA
| |
|
West and Central Europe and North America
|
45.4
|
42.7–48.1
|
203
|
293 547
|
99.5
|
< 0.0001
|
0.339
| |
- HIV Human immunodeficiency virus, ART antiretroviral therapy, UNAIDS Joint United Program on HIV, NA not applicable
